Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Andy Itsara, Clare Sun, Emily Bryer, Inhye E Ahn, Susan Soto, Hao-Wei Wang, Constance M. Yuan, Adrian Wiestner

Blood (2023) 142 (Supplement 1): 201.

https://doi.org/10.1182/blood-2023-182397

Published: 2023

Journal Articles

Ibrutinib-Associated Sudden Death in Patients with CLL

Emily Bryer, Andy Itsara, Inhye E. Ahn, Beth Kozel, Cody Peer, William D. Figg, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 4133–4134.

https://doi.org/10.1182/blood-2022-160397

Published: 2022

Journal Articles

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

Emily Bryer, Shira Paul, Jonathan Chen, Christopher Pleyer, Adrian Wiestner, Clare Sun

Blood (2022) 140 (Supplement 1): 9896–9897.

https://doi.org/10.1182/blood-2022-162365

Published: 2022

Journal Articles

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

Emily Bryer, DO, Alexander Dew, DO, MS, Elizabeth Hill, MD, Elizabeth Gil Ramirez, MD, Candis Morrison, CNP, PhD, Ashley Carpenter, RN, Monica Epstein, RN, Michael Emanuel, BSN, RN, Kevin Camphausen, MD, Jennifer Jones, MD PhD, Dickran Kazandjian, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136176

Published: 2020

Journal Articles

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Emily Bryer, DO, Michael Kallan, MS, Ting-Shaun Chiu, MS, Katerina Scheuba, David H. Henry, MD

Blood (2019) 134 (Supplement_1): 4944.

https://doi.org/10.1182/blood-2019-129316

Published: 2019

NARROW

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Ibrutinib-Associated Sudden Death in Patients with CLL

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Email alerts

ASH Publications

American Society of Hematology

Long-Term Outcomes in Chronic Lymphocytic Leukemia Treated with Ibrutinib: 10-Year Follow-up of a Phase 2 Study

Ibrutinib-Associated Sudden Death in Patients with CLL

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL

A Phase II Pilot Study of Avelumab in Combination with Hypofractionated Radiotherapy in Patients with Relapsed Refractory Multiple Myeloma

A 19-Year Retrospective Analysis of Venous Thromboembolism Trends in Chemotherapy-Induced Anemia: Red Blood Cell Transfusion Versus Erythrocyte Stimulating Agent Administration

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only